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Abstract:  A  complex  set  of  interactions  between  the  human  genes  encoding  innate 
protective functions and immune defenses and the environment of the intestinal mucosa 
with  its  microbiota  is  currently  considered  key  to  the  pathogenesis  of  the  chronic 
inflammatory  bowel  diseases  (IBD).  Probiotics  offer  a  method  to  potentially  alter  the 
intestinal  microbiome  exogenously  or  may  provide  an  option  to  deliver  microbial 
metabolic products to alter the chronicity of intestinal mucosal inflammation characterizing 
IBD. At present, there is little evidence for the benefit of currently used probiotic microbes 
in  Crohn’s  disease  or  associated  conditions  affecting  extra-intestinal  organs.  However, 
clinical practice guidelines are now including a probiotic as an option for recurrent and 
relapsing antibiotic sensitive pouchitis and the use of probiotics in mild ulcerative colitis is 
provocative and suggests potential for benefit in select patients but concerns remain about 
proof from trials. 
Keywords:  Crohn’s disease; ulcerative colitis;  pouchitis; spondyloartopathy; arthralgia; 
sclerosing cholangitis; maintenance; induction; remission 
 
1. Introduction 
A recent large-scale metagenomic sequencing study revealed the presence of a core set of bacterial 
species shared between individuals [1]. Individuals harbor at least 160 bacteria species, among which 
75 and 57 are common to more than 50% and 90% of individuals, respectively. It is now evident that 
the gut microbiota is composed of 2 components: A core set of bacteria common to everyone and 
another set whose composition varies between individuals and this intestinal microbiota gene set is 
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some 150 times larger than the host human gene complement. The existence of this variable set likely 
arises  from  functional  redundancy  in  the  bacterial  world,  but  becomes  pertinent  when  discussing 
administration  of  probiotic  strains  at  high  doses  over  long  periods  of  time  in  patients  with 
Inflammatory Bowel Diseases (IBD).  
IBD consists of chronic and relapsing inflammatory diseases of the intestines classically comprising 
of two similar yet distinct subtypes: ulcerative colitis (UC) and Crohn’s disease (CD). UC and CD 
differ by the intestinal localization and features of the inflammation. UC by definition is continuous 
inflammation starting in the rectum and restricted to the colon while CD inflammation can occur 
anywhere in the gastrointestinal tract, often with skip lesions. Microscopic lesions are restricted to the 
mucosa layer for UC while affecting the full thickness of the intestinal wall for CD [2]. 
Careful epidemiological studies have demonstrated that CD is increasing in some western countries 
and most worrisome is a steep rise in younger children [3]. Unfortunately, there is no medical cure for 
IBD and despite considerable research efforts the cause of IBD is uncertain. Recent genome wide 
association studies (GWAS) in both adults and pediatrics [4–6] have been highly successful in identify 
novel pathways in the pathogenesis of IBD and yet these GWAS have only identified 25% of the 
genetic risk for developing IBD and have yet to produce therapeutic results.  
Environmental factors also are linked with development of IBD such as amount of fibre and fats in 
diets  [7,8],  active  and  passive  tobacco  smoking  [9,10]  and  vitamin  D  deficiency  [11,12].  Indeed, 
certain living environments also seem to play a role as evidenced by studies linking the development 
of CD with living on a farm within the first 6–12 months of life [13,14] and second generation South 
Asian immigrants moving to Canada’s west coast were found to have a very high and an increasing 
incidence of IBD [15]. There was not access for all of the above studies to biologic specimens to 
assess  how  environmental  factors  might  change  host-microbe  interaction,  gut  microbe  balance  or  
gene-environment interaction. 
Some of the best evidence that the gut microbiota plays a key role in IBD comes from animal model 
studies. Although the experimental animal models of IBD do not exactly mimic human UC and poorly 
mimic CD, these studies have shown that the development of the disease is dependent on the presence 
of resident bacteria. A key finding from animal models is that in a number of separate animal models 
with induced, spontaneous or genetically engineered disease, chronic colonic inflammation is initiated 
and perpetuated in the presence of resident enteric bacteria, whereas germ-free (sterile) conditions 
prevent or dramatically attenuate the development of disease [16,17]. More recently, the loss of the 
transcriptional factor T-bet in mice, which regulates the differentiation and function of immune system 
cells,  was  shown  to  promote  the  bacterial  community  to  become  colitogenic  [18].  Moreover,  the 
induced colitis could be communicated to other genetically intact hosts by vertical transfer  of the 
colitogenic  microbiota  [18].  This  experiment  clearly  demonstrated  that  the  composition  of  the 
microbial  community  could  directly  cause  colitis  (in the same  genetic  background).  Moreover,  in 
children both the number of immune responses and the magnitude of immune response to various 
microbial  antigens  involving antibodies  to  the  Escherichia  coli  outer-membrane  porin  C (OmpC), 
Saccharomyces  cerevisiae  (ASCA)  and  anti-flagellin  antibodies  (Anti-CBir1)  were  predictive  of 
aggressive CD phenotypes [19].  
Thus, it is becoming clearer that the complex interactions between microbial, genetic, immune, and 
environmental  factors  are  critical  in  the  pathogenesis  of  IBD.  The  proposed  mechanisms  in  the Nutrients 2011, 3 
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genetically  susceptible host  that  lead  toward  aggressive  cellular  immune  responses  in  response  to 
components of the microbiota and the development of experimental colitis in mutant animals include 
loss  of  epithelial  cell  barrier  function,  overexpression  of  pro-inflammatory  mediators  in  different 
effector T lymphocyte subsets (Th1 and Th17, Th2), deficient protective and regulatory signals and/or 
abnormal antigen presentation [16,17]. This leads to a dysregulated immune response directed against 
the  intestinal  microbiota  and  results  in  a  disruption  of  the  intestinal  microbiota  equilibrium.  The 
etiology of IBD can therefore be conceptualized as an aberrant immune response to a component or 
components  of  the  gut  microbiota  potentially  triggered  following  an  environmental  insult  in  a 
genetically susceptible individual. It remains unknown whether the human gut microbiome triggers, is 
altered as a secondary response to the intestinal inflammation or maintains the chronicity of intestinal 
inflammation that is the hallmark of IBD. Nevertheless, as the majority of IBD susceptibility genes 
identified are involved in regulation of innate or adaptive immunity and maintenance of the intestinal 
mucosal barrier, it is apparent that the microbiome plays a critical role in the development and natural 
history of disease. The addition of probiotics to this complex microenvironment may thus affect at a 
number of levels including direct effects on the immunologic reaction of the host, indirectly lessen the 
immunologic reaction of the host by improving the mucosal barrier function to lessen interaction with 
the host immune system, displacement of deleterious microbes from luminal-mucosal interface or alter 
metabolic consequences of the microbiome. 
The use of probiotics has been proposed for providing benefits to human health for a long time but 
in recent years there has been increased interest for their use in inflammatory bowel disease due to the 
microbiome  role  in  IBD  pathogenesis  [20].  Probiotics  are  being  ingested  by  patients  with  IBD 
sometimes through the advice of the physician but mostly self-prescribed as a form of alternative 
medicine [21,22]. The reasons for their usage seem to be mostly related to severity of disease, side 
effects of treatments and health beliefs [21–23]. Recent reports compared to even a few years ago 
would suggest increase in the use such that up to 50% of patients with IBD or parents of children with 
IBD are at least trying probiotics if not taking on a regular basis and parents giving them to their 
affected children [21–27]. The aim of this chapter is to review information that is available at the 
current time. 
2. Ulcerative Colitis 
2.1. Treatment of Active Inflammation in Ulcerative Colitis 
A systematic review with data analysis has been performed on the first randomized trials (See 
Table 1, references [28–31]) involving probiotics for induction of remission for ulcerative colitis [32]. 
Due  to  the  significant  differences  in  probiotics,  outcomes  and  trial  methodology  and  as  outlined  
in  Table  1,  a  formal  meta-analysis  was  not  preformed.  They  are  small  trials  with  approximately  
10–52  participants  in  treatment  arms  for  participants  with  mild  to  moderate  disease  activity.  The 
probiotics  were  given  as  single  and  blends  of  microorganisms,  probiotic  in  combination  with  a 
prebiotic fructooligosaccharide/inulin mixture and combined with allopathic medicine.  
Following their systematic review, Mallon et al. [32] concluded that addition of a probiotic to 
conventional  therapy  did  not  improve  overall  remission  rates  in  patients  with  mild  to  moderate Nutrients 2011, 3 
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ulcerative colitis but the addition of probiotics may reduce disease activity. The data were analyzed 
using  intention  to  treat  for  the  three  studies  that  measured  proportion  of  patients  achieving  
remission [28,30,31].  
For these three studies: 
  probiotics  (Yakult™) + 5-ASA had similar effectiveness  to  placebo +  5-ASA  for induction of 
remission [28]: probiotic 40%, placebo 30%, OR 0.64 (95% CI 0.10 to 4.10);  
  probiotics (VSL#3™) + balsalazide had similar effectiveness to placebo + balsalazide for induction 
of remission [30]: probiotic 80%, placebo 70%, OR 0.58 (95% CI 0.18 to 1.91). 
  probiotics (E. coli Nissle 1917) + steroids had similar effectiveness to mesalazine + steroids for 
induction of remission [31]: probiotic 68.4%, mesalazine 74.6%, OR 1.35 (95% CI 0.6 to 3.04). 
As comparison, in a trial of 268 UC patients with moderate severity 4.8 g of delayed release oral 
mesalamine was found to have clinical benefit in 70% and superior to a response rate of 59% for those 
using a lower dose of 2.4 g of a delayed release oral mesalamine for moderate UC disease activity [33]. 
Table 1. Randomized Trials of probiotics as therapy of active UC. 
Participants 
(# Treated) 
Trial Design  Probiotic (Strains) 
Dosing 
(CFU/day) 
Trial Length 
(Weeks) 
References 
20 (10)  EBRPC  Blend Probiotic (Yakult™)  1 ×  10
10  12  [28] 
16 (8)  DBRPC 
Single Probiotic + Prebiotic 
(B. longum) 
4 ×  10
11  4  [29] 
90 (30)  R  Blend Probiotic (VSL#3™)  9 ×  10
11  8  [30] 
102 (52)  DBRDD  Single strain (E. coli Nissle)  1 ×  10
11  12  [31] 
29 (14)  DBRPC  Blend Probiotic (VSL#3™)  1 ×  10
11/kg  52  [34] 
120 (80)  R 
Probiotic ± Prebiotic  
(B. longum) 
2 ×  10
9  4  [35] 
90 (70)  DBRPC  Single strain (E. coli Nissle)  1–4 ×  10
9  2–8  [36] 
147 (77)  DBRPC  Blend Probiotic (VSL#3™)  7.2 ×  10
12  12  [37] 
EBRPC: Endoscopy blinded, randomized, placebo-controlled; DBRPC: Double-blind randomized 
placebo-controlled;  R:  Randomized;  DBRDD:  Double-blind,  randomized,  double-dummy;  
Blend:  combination  of  two  or  more  probiotic  organisms;  Yakult™:  B.  breve,  B.  bifidum  and 
L. acidophilus;  VSL#3™:  L.  acidophilus,  L.  plantarum,  L. paracasei,  L. bulgaricus,  B.  breve, 
B. longum, B. infantis, and S. thermophilus. 
There have been some additional randomized placebo-controlled trials studies since the Cochrane 
systematic review (Table 1 [34–37]). In a trial in children with moderate-to-severe disease VSL#3™ or 
placebo  was  administered  along  with  corticosteroids  and  mesalamine.  The  corticosteroid  dose 
(1 mg/kg/day  to  a  maximum  of  40  mg/day)  and  mesalamine  (50  mg/kg/day)  dose  were  those 
commonly used. The corticosteroids were tapered after a month if subjects were in remission. In this 
study, remission was achieved in 13 of 14 participants (92.8%) treated with VSL#3™ and IBD therapy 
and in 4 of 15 patients (36.4%) treated with placebo and IBD therapy (p < 0.001). This result must be 
taken in context the response rate to corticosteroids and mesalamine in the placebo treated group. As a 
comparison, in a multicentre North American registry reporting the outcome of children with newly 
diagnosed UC, 60% of those treated with corticosteroids were in remission at 3 months [38]. Nutrients 2011, 3 
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Using a quality of life measure Fujimori and colleagues [35] studied patients on stable doses of 
aminosalicylates and/or prednisolone for at least 4 weeks in remission or had mildly active UC. They 
reported  that  that  only  those  patients  taking  a  combination  of  a  prebiotic  and  B.  longum  had  an 
improvement (p = 0.03) whereas those subjects on the individual components (either prebiotic alone or 
probiotic individually) did not. The probiotic was taken once daily and the prebiotic twice daily and 
the study was not double dummy controlled and thus one wonders about a lack of blinding effect on 
outcome.  The  only  measure  of  disease  activity  was  C-reactive  protein  on  a  small  number  from 
each group.  
The response to rectal enemas of E. coli Nissle in subjects with distal proctitis of moderate activity 
was studied by Matthes et al. [36]. The concentration of the probiotic was 10
8 CFU/mL and subjects 
with mild to moderate disease activity were randomized to receive enemas once daily containing either 
10 mL, 20 mL, 40 mL or placebo that was volume matched the three different enema volumes used in 
the E. coli Nissle groups. Permissible concomitant therapies included loperamide drops to improve 
retention capacity for enemas, and oral UC maintenance treatment with aminosalicylates or steroids at 
a constant level for at least two weeks prior to the study. A disease activity index was used to measure 
response and if there was no response at 2 weeks, they were classified non-responders but otherwise 
could continue up to 8 weeks of therapy. In contrast to per protocol analyses, intention to treat analysis 
revealed the number of responders was not significantly higher in the E. coli Nissle group than in the 
placebo group (p = 0.4430) in this Phase II study. 
In a multicenter, randomized, double blind, placebo-controlled trial from India, Sood et al. [37] 
studied the blend probiotic VSL#3™ in adults with mild-to- moderate UC. Participants were assigned 
randomly to groups that were given 3.6 ×  10
12 CFU VSL#3 (N = 77) or placebo (n = 70) twice daily 
for 12 weeks. A primary end point of 50% decrease in the Ulcerative Colitis Disease Activity Index 
(UCDAI) at 6 weeks was achieved in a greater number of those receiving probiotic (32.5%) than the 
group given placebo (10%) (p = 0.001). A secondary end point of remission by 12 weeks was achieved 
in 33 subjects given probiotic (42.9%) compared with 11 subjects given placebo (15.7%, p = 0.001).  
2.2. Probiotics as Maintenance Therapy in Ulcerative Colitis 
Only a few probiotic products either combined as blends (n = 2) or administered as single strain 
monotherapy (n = 4) have been studied in UC maintenance trials with 3 of the single probiotic trials 
utilizing E. coli strain Nissle 1917. With a background of up to 70% relapse rate over a 1-year period 
for those with ulcerative colitis not taking any form of maintenance therapy [39], many of the trials 
have been for one year (Table 2) and studied remission rates in comparison with 5-aminosalicylate 
products [31,40,41]. One of these 12-month probiotic versus 5-aminosalicylate trials was initiated with 
active UC patients [31] and followed those achieving remission for a 12-month period. In this study 
the relapse rates were high in both the group maintained with E. coli Nissle 1917 and those maintained 
on 1.5 g of daily mesalazine (67% and 72%, respectively). The other 12-month trials were initiated in 
participants with quiescent disease. In these studies, maintenance of remission rates varied between 
45% and 75% [40–42] and studies in those receiving 5-aminosalicylates as a control group had a 
similar maintenance of remission rate as the probiotic intervention group [40,41]. Interestingly in the 
trial comparing monotherapy L. rhamnosus strain GG, monotherapy mesalamine (2.4 g per day) and Nutrients 2011, 3 
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combination probiotic and mesalamine, no synergistic benefit was derived form combination therapy 
but all three groups had equivalent rates for maintenance of remission [41]. The studies comparing 
probiotic  with  5-aminosalicylates  have  used  different  total  daily  amounts  (1.5–2.4  g  per  day). 
Nevertheless, currently there is not currently clinical evidence of a direct dose-dependent maintenance 
benefit above 1.6 g daily dosing of 5-aminosalicylate [43].  
In the small trial in children [34], the blend probiotic VSL#3™ reported 3 of 14 (21.4%) patients 
treated with VSL#3™ and their other IBD therapy and 11 of 15 (73.3%) patients treated with placebo 
and IBD therapy relapsed within 1 year of follow-up (P = 0.014; RR = 0.32; CI = 0.025–0.773). It is 
not obvious from the trials done to date that there is any advantage to blends of probiotics as compared 
to single probiotics and there are no comparative trials to answer this question. 
Table 2. Randomized Trials of probiotics used as maintenance therapy for ulcerative colitis. 
Participants 
(# Treated) 
Trial Design  Probiotic (Strains) 
Dosing 
(CFU/day) 
Trial Length 
(Months) 
References 
103 (50)  DBRDD 
Single strain 
(E. coli Nissle) 
5 ×  10
10  3  [44] 
83 (39)  DBRDD 
Single strain 
(E. coli Nissle) 
1 ×  10
11  12  [31] 
21 (11)  R  Blend (Yakult
®)  1 × 10
10  12  [42] 
327 (162)  DBRDD 
Single strain 
(E. coli Nissle) 
5 ×  10
9  12  [40] 
187 (127)  R 
Single strain 
(L. rhamnosus GG) 
1.8 ×  10
10  12  [41] 
29 (14)  DBRPC 
Blend Probiotic 
(VSL#3™) 
1 ×  10
11/kg  12  [34] 
Same footnotes as Table 1. 
2.3. Pouchitis 
Proctocolectomy with ileal pouch-anal anastomosis may be required in some UC patients because 
their disease was medically intractable or they developed secondary dysplasia or cancer. Pouchitis or 
inflammation of the ileal reservoir created during the procedure may develop in between 15 and 50% 
in patients. It is the most common complication of the surgery and although the exact etiology is not 
clear  host  genetic  factors,  local  pouch  issues  and  the  microbiota  contained  within  the  pouch  are 
thought to be involved [45,46]. 
Most patients will develop this problem in the first year and antibiotics can be an effective form of 
therapy in many [45,46] but for those that do not respond the term antibiotic-resistant is applied and 
these patients can be chronically active requiring other forms of therapy [46]. For some, antibiotics 
improve the pouchitis but there is a relapsing course of the pouchitis following the discontinuation of 
antibiotics. As antibiotics can provide relief for most with pouchitis, a basic assumption has been the 
importance of the microbiota of the  pouch  in the development and  chronicity  of pouchitis. Thus, 
alteration of the microbiota by addition of probiotics was considered. Subsequently, probiotics for 
treatment  of  acute  pouchitis,  prevention  of  initial  onset  of  pouchitis  and  prevention  of  relapsing 
pouchitis have all been evaluated.  Nutrients 2011, 3 
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2.3.1. Probiotics as Treatment of Pouchitis 
Trials  for  treating  mild/moderate  pouchitis  are  few  with  small  numbers  of  adult  participants. 
Kuisma et al. [47] recruited 20 patients (10 intervention arm) for a DBRPC trial of L. rhamnosus GG 
2 ×  10
10 CFU/day for 3 months. Those patients with chronic, active pouchitis were excluded. The 
Pouchitis Disease Activity Index [48] was utilized for evaluation of clinical effect. Prior to study entry, 
the mean  PDAI  was in the  mild range  (8.0  ±  0.8)  and  no there was no difference  following  the 
intervention period with clinical response (defined as a PDAI score reduction of ≥3) occurring in  
1/10 (10%) patients in the probiotic group and 0/10 (0%) patients in the placebo group (10% vs. 0%, 
P = 0.32).  
In an open-label trial of 51 UC patients post ileal pouch-anal anastomosis using a fermented milk 
product with a blend of probiotic strains (L. acidophilus strain La5 + B. lactis strain Bb12) containing 
5 ×  10
10  CFU/day  [49]  however,  there  was  a  reported  improvement  in  endoscopic  evaluation.  In 
another  open  label  trial  twenty-three  consecutive  patients  with  mild  pouchitis  as  defined  using 
Pouchitis Disease Activity Index (scores 7–12) were treated with 3.6 ×  10
12 CFU/day of VSL#3™ for 
four  weeks  [50].  Sixteen  of  23  patients  (69  percent)  with  mild  pouchitis  were  in  remission  after 
treatment  and  the  median  total  Pouchitis  Disease  Activity  Index  scores  reported  before  therapy 
improved following therapy (10 versus 4, P < 0.01).  
Thus, there is limited evidence for a role of probiotics as monotherapy for mild/moderate pouchitis 
at  the  present  time.  Limiting  access  of  microbiota  to  the  mucosa  of  the  pouch  and  subsequent 
development  of  inflammation  may  be  a  key  mechanism  whereby  probiotics  provide  benefit. 
Alternatively, changing the composition of the pouch microbiota may be important; although it is 
interesting that no long-term colonization of probiotic strains is achieved [51]. Thus it may not be 
surprising  that  once  the  deleterious  microbiota  have  colonized  within  the  pouch  there  is  little  a 
probiotic as monotherapy can do to alter the situation. A somewhat analogous situation exists for use 
of  probiotics  as  monotherapy  in  treating  Helicobacter  pylori.  The  eradication  rate  of  probiotic 
monotherapy was poor compared to standard triple therapy (a proton pump inhibitor + 2 antibiotics) in 
children  colonized  with  H.  pylori  [52].  Interestingly,  a  number  of  studies  have  reported  indirect 
evidence  suggested  reduced  H.  pylori  colonization  with  probiotic  monotherapy  even  though 
eradication rate is poor [53] and one study suggested reduced gastritis on biopsy [54]. The increased 
eradication rates of H. pylori using combined probiotic and antibiotic may take advantage of lower 
levels of pathogen in the stomach and/or decreased adverse effects of the antibiotics. Thus, if there is 
an analogy to be drawn for it would be interesting in future studies of patients with pouchitis requiring 
continuous antibiotics or very frequent use of antibiotics whether probiotics had a role following short 
antibiotic courses of therapy.  
2.3.2. Prevention of Initial Post-Operative Onset of Pouchitis  
Two trials have studied whether there is an advantage to initiate probiotics immediately following 
ileal pouch-anal anastomosis and both found there to be benefit to the delay in onset of development of 
pouchitis. One of these was a placebo-controlled trial [55] In this controlled trial at the end of one year 
2 of 20 (10%) of those in the intervention arm had developed colitis as determined compared to  Nutrients 2011, 3 
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8 of 20 (40%, no episodes 80% versus 60%, P = 0.03) of the control arm participants using the PDAI 
with endoscopy. The Peto odds ratio for prevention of pouchitis by VSL#3™ compared with placebo 
was 4.76, 95% CI 1.16 to 19.56 [56].  
The  other  randomized  trial  or  probiotics  also  studied  VSL#3™  in  an  open-label  design  that 
compared the probiotic to no treatment over a 12 month period [57]. None of the 16 patients in the 
group administered probiotic compared to one of 12 (8.3%, no pouchitis 100% versus 92%, p = 0.24) 
developed pouchitis.  
2.3.3. Maintenance of Pouchitis Remission (Table 3)  
The initial controlled trial for this indication was in the year 2000 using the blend probiotic product, 
VSL#3™ and reported on outstanding effect in prevention of the recurrence of pouchitis in patients 
with antibiotic-dependent pouchitis. Prior to the administration of the blend probiotic, participants in 
his trial were successfully treated with a combination of antibiotics (ciprofloxacin + rifaximin). At the 
end of the study period of 9 months, only 3 of 20 (15%) had developed pouchitis in the intervention 
group whereas all 20 participants in the control group had a recurrence of pouchitis and this had 
occurred 4 months following the antibiotics [58]. A similar result was noted in another European trial 
of VSL#3™ that also evaluating the prevention of recurrence of pouchitis in relapsing or chronic 
pouchitis patients [51]. Remission of the pouchitis was induced in these participants by administering 
4 weeks of a combination of antibiotics (metronidazole + ciprofloxacin) that was followed by either 
VSL#3™ or a placebo. In the treatment group remission was maintained in 17 of 20 (85%) but only 
1 of  16  (6%,  p  <  0.0001)  on  placebo.  The  pooled  Peto  odds  ratio  for  these  two  studies  for  the 
combined rate of maintenance of remission with probiotic bacteria compared to placebo (97% versus 
3%, P < 0.0001) was 25.39 (95% CI 10.37 to 62.17). The number needed to treat with oral probiotic 
therapy to prevent one additional relapse was 2 [56]. 
Table 3. Randomized trials of probiotics in prevention of onset or recurrence of pouchitis. 
Participants 
(# Treated) 
Trial Design  Probiotic (Strains) 
Dosing 
(CFU/day) 
Trial Length 
(Months) 
References 
40 (20)  DBRPC  Blend (VSL#3™)  9 ×  10
11  12  [55] 
31 (16)  R  Blend (VSL#3™)  9 ×  10
11  12  [57] 
40 (20)  DBRPC  Blend (VSL#3™)  1.8 ×  10
12  9  [58] 
36 (20)  DBRPC  Blend (VSL#3™)  9 ×  10
11  12  [51] 
Same footnotes as Table 1. 
In contrast, an open label trial by Shen and colleagues [59] reported lesser responses. In their trial, 
31 subjects were  prescribed  a  2-week treatment of a  single  antibiotic (ciprofloxacin)  followed by 
VSL#3™. Also in contrast to the other studies, the VSL#3™ was bought by patients rather than be 
supplied through the study. Probiotic therapy was stopped by 9 of 31 (29%) seven weeks into therapy 
and 25 of 31 (81%) by 8 months had discontinued the probiotic because of failure to prevent pouchitis 
(n = 23) or side effects of the probiotic administration (n = 2). Only 6 of 31 (19%) did not develop 
clinical evidence of pouchitis by the end of the 8-month trial period. Even among these 6 subjects 
endoscopy revealed some level of pouch inflammation. In this trial [59], there was a single antibiotic Nutrients 2011, 3 
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administered  and  endoscopy  was  not  performed  prior  to  probiotic  administration  to  ensure  pouch 
inflammation had completely resolved.  
A recent clinical practice guideline on management of pouchitis [46] has suggested that for those 
patients with prompt recurrence of pouchitis following antibiotic usage or having multiple recurrences 
of pouchitis despite antibiotics either VSL#3™ or chronic use of antibiotics but does not suggest 
probiotics for acute treatment of pouchitis.  
4. Crohn’s Disease 
4.1. Treatment of Active Crohn’s Disease Inflammation 
There is a paucity of studies that have investigated use of probiotics to settle active inflammation. 
For two open label studies [60,61], probiotics (using combination of B. breve + L. casei + B. longum + 
prebiotics or L. rhamnosus GG, respectively) were added to immunomodulators and corticosteroids. In 
the former study [60] in 7 of 10 patients were reported to respond as determined by Crohn’s Disease 
Activity  Index  scores  with  most  noticeable  improvement  in  the  diarrhea.  However,  there  was  no 
improvement in inflammation as measured by erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP). In the open label trial using L. rhamnosus GG [61], 3 of the 4 children were reported to 
have improved Pediatric Crohn’s Disease Index (PCDAI) scores or serial determinations over the 
6 months  of  the  trial.  Specifics  with  regards  to  ESR  or  CRP  are  not  reported  but  the  ESR  is  a 
component of the PCDAI [62].  
A  placebo-controlled  trial  using  L.  rhamnosus  GG  was  the  sole  study  included  in  a  Cochrane 
review of efficacy of probiotic supplementation for the induction of remission in CD that met the 
inclusion criteria of being a randomized controlled trials of participants with Crohn’s disease whose 
disease was active at the time of entry into the study [63]. There were a total of 11 participants in the 
study  and  subjects  received  antibiotics  and  concurrent  therapy  of  corticosteroids  and  some 
methodological concerns were raised. Four of 5 patients in the probiotic group achieved remission 
compared to 5 of 6 in the placebo group (OR 0.80; 95% CI 0.04 to 17.20). Thus, this one small study 
did not show that probiotics had any effect in treating active Crohn’s disease. At best, one could say 
there  is  insufficient  evidence  to  make  any  conclusions  about  the  effectiveness  of  probiotics  for 
treatment of active Crohn’s disease. 
4.2. Probiotics as Maintenance Therapy for Crohn’s Disease 
Initial randomized trials (See Table 4) in Crohn’s disease were reported with probiotics used as sole 
maintenance  therapy  following  corticosteroid  therapy  [64]  or  in  combination  with  lower  does  of  
5-aminosalicylate  therapy  compared  to  controls  for  maintenance  therapy  in  those  already  in 
remission [65]. Subsequent trials have focused on L. rhamnosus strain GG for maintenance therapy 
following induction of remission with corticosteroids [66] and maintenance of remission with probiotic 
used as additional maintenance therapy [67]. There were no differences in the number of relapses in 
patients  receiving  E.  coli  Nissle  compared  to  the  placebo  (P  =  0.11),  Saccharomyces  boulardii 
(1 g/day) plus mesalazine (2 g/day) compared to mesalazine alone (3 g/day) (P = 0.08), or patients 
with patients with remission induced medically receiving L. rhamnosus GG (P = 0.77). Nutrients 2011, 3 
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Table 4. Randomized trials of probiotics in Crohn’s disease maintenance. 
Participants 
(# Treated) 
Trial Design  Probiotic (Strains) 
Dosing 
(CFU/day) 
Trial Length 
(Months) 
References 
28 (16)  DBRPC 
Single strain 
(E. coli Nissle 1917) 
5 ×  10
10  12  [64] 
32 (16)  R 
Single strain  
(S. boulardii) 
N/A
  6  [65] 
11 (5)  DBRPC 
Single strain 
(L. rhamnosus strain GG) 
2 ×  10
9  6  [66] 
75 (39)  DBRPC 
Single strain 
(L. rhamnosus strain GG) 
2 ×  10
10  24  [67] 
Same footnotes as Table 1. 
In the largest maintenance trial to date, Bousvaros et al. [67] also reported no difference in the 
proportion of those developing relapse on L. rhamnosus strain GG 2 ×  10
10 CFU/day (31%; 12 of 39) 
or placebo (17%; 6 of 36, p = 0.18). The time to relapse is shown in Figure 1, and although the 
probiotic group trended to a shorter time to relapse, comparison between it and the control group on 
placebo was not statistically different (p = 0.10). 
Two other studies reported in abstract are reviewed in Cochrane review on probiotics for Crohn’s 
maintenance. In the review no difference in subjects receiving  L. rhamnosus GG plus mesalazine 
compared to those receiving the same level of maintenance therapy without probiotic as determined by 
CDAI  in  one  abstract  and  no  difference  in  endoscopic  relapse  using  for  VSL#3™  compared  to 
mesalamine alone in the other abstract [68]. This must be taken in the context that mesalamine has no 
benefit for maintenance of Crohn’s disease in itself [69].  
Figure  1.  Kaplan-Meier  survival  curve  showing  the  probability  of  staying  relapse-free 
during  the  duration  of  the  study  treatment  duration  for  participants  administered 
L. rhamnosus GG or placebo. Reproduced with permission from John Wiley and Sons [67].  
 Nutrients 2011, 3 
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4.3. Probiotics for Prevention of Post-Operative Crohn’s Disease Recurrence 
Another aspect of Crohn’s disease that has been studied is that of prevention of recurrence of 
disease following surgical resections and details as to the trials are included in Table 5. There are 
however, 5 randomized trials [70–74] that have been published. Three of the trials involved single 
probiotic strains being administered and 2 trials included combination probiotics. In the L. rhamnosus 
GG  trial  [70],  9  of  15  (60%)  in  L.  rhamnosus  GG  group  in  clinical  remission  had  endoscopic 
recurrence  and  6  of  17  (35%)  in  placebo  group  in  clinical  remission  had  endoscopic  recurrence  
(p = 0.297). In the first L. johnsonii LA1 trials [71], at 6 months endoscopic recurrence was seen in 
21 of 43 (43%) in L. johnsonii LA1 group and 30 of 47 (64%) of placebo group and (p = 0.15). The 
second L. johnsonii LA1 trial [72] also showed similar overall endoscopic scores between the probiotic 
and placebo groups (P = 0.48) and similar numbers of those with severe endoscopic recurrence with 
21% of those taking L. johnsonii LA1 versus 15% taking placebo (P = 0.33). None of the secondary 
outcomes (clinical recurrence, histological score, C-reactive protein) showed any difference either. 
Similarly, the 2 studies using a blend of probiotics failed to reveal any differences between treatment 
and placebo groups for endoscopic recurrence [73,74]. A meta-analysis [75] of the effects of probiotics 
as  a  class  suggested  that  their  effect  was  no  different  than  placebo.  The  relative  risk  of  clinical 
recurrence with any probiotic relative to placebo (n = 213) was 1.41 (95% CI 0.59 to 3.36), any 
endoscopic recurrence (n = 333) was 0.98 (95% CI 0.74 to 1.29) and severe endoscopic recurrence 
(n = 213) was 0.96 (95% CI 0.58 to 1.59).  
Table 5. Double-blind placebo controlled trials of probiotics for prevention of post-operative 
Crohn’s disease recurrence.  
Participants 
(# Treated) 
Probiotic (Strains) 
Dosing 
(CFU/day) 
Trial Length 
(Months) 
References 
45 (23) 
Single Strain 
(L. rhamnosus GG) 
1.2 ×  10
9  12  [70] 
98 (48) 
Single Strain 
(L. johnsonii LA1) 
4 ×  10
9  6  [71] 
70 (34) 
Single Strain 
(L. johnsonii strain LA1) 
10
10  3  [72] 
30 (2) 
Blend Probiotics + Prebiotics 
(P. pentoseceus, L. raffinolactis, 
L. paracasei susp paracasei 19 
and L. plantarum 2362) 
10
10  24  [73] 
120 (58) 
Blend Probiotics 
(VSL#3™) 
1.8 ×  10
12  3  [74] 
Same footnotes as Table 1. Nutrients 2011, 3 
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5. Associated Conditions 
5.1. Arthralgia 
In  an  open  label  trial  with  a  dropout  rate  of  45%,  16  patients  with  either  Crohn’s  disease  or 
ulcerative  colitis  completed  a  3-month  trial  of  ingesting  9  ×   10
11  CFU/day  of  a  blend  probiotic 
(VSL#3™) to assess whether there was a clinical improvement in arthralgia [76]. Participants had 
quiescent IBD at entry and no clinical or laboratory evidence of arthritis, were not taking non-steroidal 
anti-inflammatory medications and other medications were unchanged. An improvement in peripheral 
but not axial arthralgia was reported using an articular index score but no joint pain improvement as 
reported using a patient-completed visual analog scale. 
5.2. Spondylarthropathy 
In  an  interesting  internet-based  randomized  control  trial  [77]  of  probiotic  in  patients  with 
spondylarthropathy included some 7% with concomitant IBD. The primary aim of the study was to 
determine whether an internet-based trial of a complementary and alternative medicine could fulfill the 
revised  CONSORT  (Consolidated  Standards  of  Reporting  Trials)  statement  quality  checklist  for 
reporting of RCTs. However a secondary aim was to study the effect of probiotics on improving  
well-being.  Well-being  was  measured  by  self-assessment  using  a  visual  analog  scale  and  96  of 
147 (65%)  of  people  randomized  to  receive  a  blend  probiotic  completed  a  3-month  trial.  No 
statistically or clinically significant difference between placebo and probiotic groups in terms of global 
well-being was determined in the study [77]. 
5.3. Sclerosing Cholangitis 
Fourteen participants with concurrent IBD were randomized to treatment with a blend probiotic 
(L. acidophilus,  L.  casei,  L.  salivarius,  L.  lactis,  B.  bifidum  and  B.  lactis;  total  daily  dose  of 
10
10 CFU/day) or placebo during 3 months in a double-blind crossover design that included a 1-month 
washout period [78]. The subjects remained on their ursodeoxycholic acid. The results of this study 
showed no evidence of a beneficial effect of the probiotics on PSC-related symptoms, serum liver 
biochemistry or liver function. 
6. Summary 
It is important to not generalize reports of positive benefit from specific strain studies to species 
effects as it is equally as important not to generalize negative reports of a specific strain to a species 
effect. In addition, all reviews clearly acknowledge the need for further studies with regards to dosing, 
duration of therapy, delivery methods and whether blends of different strains of probiotics offer any 
benefit over single strains. That being said, clinical practice guidelines are now including a probiotic 
(i.e., VSL#3™) for recurrent and relapsing antibiotic sensitive pouchitis. Use of probiotics in UC is 
provocative and suggests potential for benefit in select patients but concerns remain about proof from 
trials.  Costs  can  be  a  barrier  since  few  funders  of  health  care  (e.g.,  North  American  insurance 
companies or Government plans) cover the costs of probiotics for maintenance therapy. Certainly for Nutrients 2011, 3 
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those intolerant to 5-aminosalicylate products specific probiotic products would appear to have more 
potential for modest effect in maintenance of remission for those with mild/moderate disease activity.  
In contrast, there is no evidence that patients with Crohn’s disease will benefit from ingestion of 
probiotics for any aspect of their disease whether it is for treating active disease, maintaining remission 
or preventing post-operative recurrence of disease. Neither is there benefit reported in some of the IBD 
associated conditions in the small trials that have been reported to date.  
One could speculate that since CD involves  inflammation  of the full  thickness of the mucosa, 
therapy such as microbes interacting at the mucosal-luminal interface would be less likely to have 
efficacy than with ulcerative colitis. However, this may be simplistic as more likely modulating the 
bacteria luminal  mucosal epithelial  cell  interface is  not  as  important in  Crohn’s disease as innate 
immune defects that don’t exist in ulcerative colitis. Despite these dismal results for CD, there are a 
number of novel strategies and approaches to consider that may hold hope for this form of therapy. 
Currently,  most  probiotics  include  various  strains  of  Lactobacillus  or  Bifidobacterium.  Perhaps 
microorganisms that have been found to be deficient in microbiota studies of CD patients such as 
Faecalibacterium  prausnitzii  [79]  or  others  found  to  be  increased  with  certain  diets  and  have  an  
anti-inflammatory  effect  such  as  Enterococcus  durans  [80,81]  will  prove  to  provide  a  CD  health 
benefit. In addition, genetics is an integral part of the pathogenesis of CD and genetic make-up of the 
human host has not been explored in probiotic trials. Perhaps combining specific microbes with a 
specific  host  genotype  might  be  necessary  for  efficacy.  Another  possibility  may  be  the  use  of 
genetically altered microorganisms to deliver specific genes to the mucosa microbiome might also 
provide a health benefit [82,83], albeit administration of genetically modified microbes to humans will 
require significant safety studies.  
Given the current situation of parental and self-prescribing of alternative care products including 
those described as probiotics, it behooves those providing care for IBD patients to know exactly all 
prescription and non-prescription items being administered to IBD patients so when problems in care 
are occurring comprehensive strategization of this care can be co-coordinated. Among the most serious 
clinical scenarios to consider is that in which a patient is initiating immunosuppressive therapy. While 
most  patients  undergo  the  initiation  of  immune  altering  medications  without  incident, 
immunosuppression is a possibility. There is no evidence for the use of probiotics in any form of 
severe  IBD  and  little  clinical  experience  in  the  use  of  probiotics  administration  to  severely 
immunocompromised IBD patients. However, in ill patients in ICU settings fungemia has developed 
from the use of S. boulardii as probiotic [84] and sepsis from a Lactobacillus strain has also been 
reported in an ulcerative colitis patient [85]. With commercialization of probiotics ahead of scientific 
and clinical investigation, as practitioners we should demand that the various aspects of IBD care are 
critically appraised before encouraging patients to ingest undocumented probiotic products as therapy 
in IBD. 
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